Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs

Generally, in the trials, an observant patient is described as correctly taking 90 to 100% of the prescribed doses. Here, the 80% compliance rate will be the cut-off between observant and non-observant patients. The evaluation methodology is based primarily on a survey of patients with metastatic or locally advanced kidney cancer who have just began an oral treatment protocol. The constitution of this cohort will be made from newly treated patients included by oncologists. The survey consists of implementing a series of questionnaires with each patient of the sample throughout the course of oral cancer care. This series of questionnaires will aim to identify: * the gradient of compliance of the patient with his treatment, * all the factors likely to influence positively or negatively the latter, whether medical, material or socio-economic, * the evolution of patient compliance during their treatment course, * a patient's quality of life index through the standardized quality of life survey form (EORTC - Quality of Life Questionnaire QLQ C30 version 3). * These questionnaires will be supplemented by the medical record data (including information on tolerance and possible drug interactions). The representativeness of the patients surveyed will be established by comparing the statistical characteristics of the surveyed population with those of the aggregate anonymous global data obtained by the two Medical Department of the French Regional Health Insurance of the two regions. From the data compiled by this study, different econometric models of patient behavior will seek to establish, in particular, a relationship between the probability that a given patient will be either non or poorly observant and the various variables proved to be statistically significant.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* Adult patient
* Patient with metastatic or locally advanced kidney cancer
* Patient initiating for the first time an oral route anticancer drug : Sutent® (sunitinib), Nexavar® (sorafenib), Afinitor® (everolimus), Votrient® (pazopanib) and Inlyta® (axitinib) and Cabometyx® (cabozantinib)
* Patient having signed an informed consent
* Patient treated outside interventional clinical trial

Exclusion Criteria:

* Patient with cancer other than kidney cancer
* Patient with non-extensive kidney cancer
* Patient treated by surgery, radiotherapy and intravenous chemotherapy exclusively
* Patient unable to undergo protocol monitoring
* Patient included in an interventional trial
* Patient refusing a survey at home or having hearing problems
* Other medical conditions that may interfere with the understanding of the informed consent document, with the assessment of tolerance and the response to questionnaires
* Patient with another condition deemed incompatible with the patient's inclusion into the protocol.
* Patient under guardianship or trusteeship, deprived of liberty, underage patient or pregnant woman
* Patient not affiliated with a social security system beneficiary of such a scheme